Prospective observational study on the efficacy and tolerability of a complex of phytochemicals vs. dutasteride in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

Submitted: August 5, 2024
Accepted: September 12, 2024
Published: October 2, 2024
Abstract Views: 117
PDF: 56
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Introduction: The aim of our study was to treat two similar groups of patients suffering from BPH: one group with a complex based on phycocyanin, PEA and selenium; the other group with dutasteride. So the effectiveness of these treatments was checked, especially regarding the improvement of LUTS and the reduction of PSA and prostate volume.

Materials and methods: We included 104 patients in the study. All patients aged between 50 and 70 years, PSA values between 4 and 10 ng/ml, prostate volume calculated by transrectal ultrasound between 50 and 70 cc, flowmetry with maximum flow value greater than or equal to 10 ml/s, no suspicious nodules on DRE, no suspicious lesions on MRI (PI-RADS 1-2), negative previous prostatic biopsies or never bioptied, moreover absence of diabetes mellitus or chronic renal failure (blood creatinine >2 mg/dl). We considered: -Group A of 54 men who used the complex; -Group B of 50 patients treated with dutasteride. Then we controlled all patients 6 months after starting therapy, considering the following parameters: PSA, prostate volume, flowmetry.
Results: Our results showed that both dutasteride and complex decreased PSA levels (both had a p<0.0001), with a more significant contribution of dutasteride (mean decrease of -2.743 ng/ml vs -0.971 ng/ml). Uroflowmetry also improved with both ( p<0.0001) with a mean increase in maximum flow of urine of + 3.03 ml/min for the former and + 13.02 ml/min for the latter. Lastly, dutasteride proved to be highly effective on reducing the prostate volume on TRUS (- 22.14 ml, p<0.0001) compared to Ficoxpea, which showed a mean decrease of – 10.04 ml (p<0.0001). Moreover the consistent reduction in prostate volume obtained through the use of dutasteride proved to be more intense than the one obtained by using the complex even in statistical analysis (p<0.0001).
Conclusions: Both Ficoxpea and Dutasteride showed reduction of PSA values after 6 months of treatment. The complex based on phycocyanin, PEA and selenium showed a statistically significant improvement in urinary flow, while dutasteride acts more on the volume of the prostate. However, the natural complex is a product with good efficacy on the phlogistic component and does not have the side effects of dutasteride (e.g. gynecomastia, reduced libido). Therefore, we believe it can be used by a large part of the population, in order to reduce LUTS and PSA and improve urinary flow, without side effects.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3:e754-e776.
Blankstein U, Van Asseldonk B, Elterman DS. BPH update: medical versus interventional management. Can J Urol. 2016;23:10-5.
Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22:7-17.
Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, et al. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients. Sci Rep. 2021;11:19401.
Cai T, Cui Y, Yu S, et al. Comparison of Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. Am J Mens Health. 2020;14:1557988320905407.
Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, et al. clinical benefit of tamsulosin and the hexanic extract of Serenoa repens, in combination or as monotherapy, in patients with moderate/severe LUTS-BPH: a subset analysis of the QUALIPROST study. J Clin Med. 2020;9:2909.
Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019;91:139.
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174:1349-1365.
LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther. 2006;319:1051-61.
Pessina F, Capasso R, Borrelli F, et al. Protective effect of palmitoylethanolamide in a rat model of cystitis. J Urol. 2015;193:1401-8.
D'Amico R, Genovese T, Cordaro M, et al. Palmitoylethanolamide/baicalein regulates the androgen receptor signaling and NF-κB/Nrf2 pathways in benign prostatic hyperplasia. Antioxidants 2021;10:1014.
Bergandi L, Apprato G, Silvagno F. Antioxidant and anti-inflammatory activity of combined phycocyanin and palmitoylethanolamide in human lung and prostate epithelial cells. Antioxidants. 2022;11:201.
Cordaro M, Impellizzeri D, Siracusa R, et al. Effects of a comicronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. Toxicol Appl Pharmacol. 2017;329:231-240.
Arias-Chávez DJ, Mailloux-Salinas P, Ledesma Aparicio J, et al. Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH. J Cell Mol Med. 2023;27:3147-3156.
Kok DE, Kiemeney LA, Verhaegh GW, et al. A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. Oncotarget. 2017;8:10565-10579.
Traish AM. Health risks associated with long-term finasteride and dutasteride use: it's time to sound the alarm. World J Mens Health. 2020;38:323-337.
Garcia-Argibay M, Hiyoshi A, Fall K, Montgomery S. Association of 5α-reductase inhibitors with dementia, depression, and suicide. JAMA Netw Open. 2022;5:e2248135.
Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15:463.
Kwon YK, Choe MS, Seo KW, et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol. 2010;51:266-70.
Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111:304-11.

How to Cite

Saitta, G., Mantovani, F. A., Calabrese, B., Aliboni, C., Di Paola, G., Meazza, A. L., & Seveso, M. (2024). Prospective observational study on the efficacy and tolerability of a complex of phytochemicals vs. dutasteride in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Archivio Italiano Di Urologia E Andrologia, 96(3). https://doi.org/10.4081/aiua.2024.12869

Similar Articles

You may also start an advanced similarity search for this article.